enGene Cuts Workforce by Half Amid FDA Filing Push for Bladder Cancer Therapy
Event summary
- enGene reduced its workforce by 50% in June 2026 to streamline operations and preserve cash.
- Interim data from the LEGEND trial's pivotal Cohort 1 showed a 54% complete response rate in high-risk NMIBC patients.
- The company plans to meet with the FDA in the second half of 2026 to discuss a Biologics License Application (BLA) filing for detalimogene.
- enGene initiated a new cohort in the LEGEND trial incorporating a surfactant bladder rinse to potentially enhance efficacy.
- Key executive departures include the Chief Financial Officer, Chief Legal Officer, and Chief Strategy and Operations Officer.
The big picture
enGene's strategic pivot to streamline operations and focus on key milestones reflects the broader trend in biotech of balancing aggressive clinical development with financial prudence. The company's push for FDA approval of detalimogene comes at a time when non-viral gene therapies are gaining traction, potentially offering advantages over traditional viral-based approaches. The leadership transition and workforce reduction underscore the challenges of maintaining momentum in a competitive and capital-intensive sector.
What we're watching
- Regulatory Strategy
- Whether the FDA meeting in the second half of 2026 will pave the way for a successful BLA submission for detalimogene.
- Clinical Efficacy
- The impact of the surfactant bladder rinse cohort on the overall efficacy and durability of detalimogene.
- Financial Stability
- The pace at which enGene can sustain its operations with the reduced workforce and existing cash reserves.
Related topics